Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward

AK Nanayakkara, HW Boucher… - CA: a cancer journal …, 2021 - Wiley Online Library
Infection is the second leading cause of death in patients with cancer. Loss of efficacy in
antibiotics due to antibiotic resistance in bacteria is an urgent threat against the continuing …

Clinical epidemiology and case fatality due to antimicrobial resistance in Germany: a systematic review and meta-analysis, 1 January 2010 to 31 December 2021

M Roedenbeck, O Ayobami, T Eckmanns… - …, 2023 - eurosurveillance.org
Background Antimicrobial resistance (AMR) is of public health concern worldwide. Aim We
aimed to summarise the German AMR situation for clinicians and microbiologists. Methods …

Immunization with lytic polysaccharide monooxygenase CbpD induces protective immunity against Pseudomonas aeruginosa pneumonia

F Askarian, CM Tsai, G Cordara… - Proceedings of the …, 2023 - National Acad Sciences
Pseudomonas aeruginosa (PA) CbpD belongs to the lytic polysaccharide monooxygenases
(LPMOs), a family of enzymes that cleave chitin or related polysaccharides. Here, we …

Understanding and managing sepsis in patients with cancer in the era of antimicrobial resistance

C Gudiol, A Albasanz-Puig, G Cuervo… - Frontiers in …, 2021 - frontiersin.org
Sepsis is a frequent complication in immunosuppressed cancer patients and hematopoietic
stem cell transplant recipients that is associated with high morbidity and mortality rates. The …

[HTML][HTML] Pseudomonas aeruginosa: Infections and novel approaches to treatment “Knowing the enemy” the threat of Pseudomonas aeruginosa and exploring novel …

N Sathe, P Beech, L Croft, C Suphioglu, A Kapat… - Infectious Medicine, 2023 - Elsevier
Pseudomonas aeruginosa is an aerobic Gram-negative rod-shaped bacterium with a
comparatively large genome and an impressive genetic capability allowing it to grow in a …

[HTML][HTML] Prolonged vs short-term infusion of β-lactam antibiotics for the treatment of febrile neutropenia: a systematic review and meta-analysis

J Laporte-Amargos, M Ulldemolins, M Puig-Asensio… - Journal of Infection, 2023 - Elsevier
Background The optimization of the use of β-lactam antibiotics (BLA) via prolonged infusions
in life-threatening complications such as febrile neutropenia (FN) is still controversial. This …

Risk Factors and Outcomes of Antibiotic-resistant Pseudomonas aeruginosa Bloodstream Infection in Adult Patients With Acute Leukemia

Y Zhao, Q Lin, L Liu, R Ma, J Chen… - Clinical Infectious …, 2020 - academic.oup.com
Background Pseudomonas aeruginosa (PA) bloodstream infection (BSI) is a common
complication in patients with acute leukemia (AL), and the prevalence of antibiotic-resistant …

Management strategies for severe Pseudomonas aeruginosa infections

H Do Rego, JF Timsit - Current Opinion in Infectious Diseases, 2023 - journals.lww.com
Carbapenem resistance in difficult-to-treat P. aeruginosa (DTR-PA) strains is primarily
mediated by loss or reduction of the OprD porin, overexpression of the cephalosporinase …

Real-life use of ceftolozane/tazobactam for the treatment of bloodstream infection due to Pseudomonas aeruginosa in neutropenic hematologic patients: a matched …

A Bergas, A Albasanz-Puig… - Microbiology …, 2022 - Am Soc Microbiol
We sought to assess the characteristics and outcomes of neutropenic hematologic patients
with Pseudomonas aeruginosa (PA) bloodstream infection (BSI) treated with ceftolozane …

Pseudomonas aeruginosa Bloodstream Infections in Patients with Cancer: Differences between Patients with Hematological Malignancies and Solid Tumors

C Royo-Cebrecos, J Laporte-Amargós, M Peña… - Pathogens, 2022 - mdpi.com
Objectives: To assess the clinical features and outcomes of Pseudomonas aeruginosa
bloodstream infection (PA BSI) in neutropenic patients with hematological malignancies …